Loading, Please Wait...

CST: 18/07/2018 06:57:03   

bioAffinity Technologies to Present at Biotech Showcase™ Annual Conference

193 Days ago

SAN ANTONIO, Texas, Jan. 05, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced that it will present its proprietary technology to detect and treat multiple cancers at the cellular level at Biotech Showcase™ 2018, an annual investor conference for the biotech industry.

bioAffinity Technologies CEO Maria Zannes will present bioAffinity’s breakthrough platform that specifically and selectively targets cancer cells on Tuesday, Jan. 9, at 4:45 p.m. in the Yosemite Room at the Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA.

Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference that gives private and public biotechnology and life sciences companies the opportunity to meet with investors and pharmaceutical executives at the J.P. Morgan Annual Healthcare Conference, one of the industry's largest annual healthcare investor conferences.

Sara Demy-Colton, CEO of Demy-Colton, said, “We are delighted that bioAffinity Technologies will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company that develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells.  Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas San Antonio. The Company’s initial product is CyPath® Lung, a diagnostic assay for the detection of early-stage lung cancer.

Contact:  Maria Zannes, 505.400.9747